Discover comprehensive details about Migalastat, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Amicus Therapeutics ( FOLD) provided updates and a final analysis plan for its second phase III study (Study 012) on migalastat HCl as a monotherapy in Fabry patients with amenable mutations. Amicus' ...
New data show the therapy led to minimal changes in renal function, even after more than 8 years. New long-term data show that patients with Fabry disease who are treated with migalastat (Galafold) ...
Review the side-effects of Migalastat as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
The evaluation committee reviewed the data available on the benefits and costs of migalastat, having considered evidence on the nature of Fabry disease and the value placed on the benefits of ...
(HealthDay News) — For patients with Fabry’s disease, the percentage of patients with response at six months does not differ for those treated with the oral pharmacologic chaperone migalastat or with ...
Credit: Getty Images. The extension study included a total of 84 adult FD patients who completed the FACETS, ATTRACT, or AT1001-041 study. The following article features coverage from the 17th Annual ...
PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare ...
PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines ...
I'm going to be taking a look at orphan drugs and their underlying companies all throughout the month of February, which will result in a number of write-ups with one specific theme: orphan drug ...
The evaluation committee (section 8) considered evidence submitted by Amicus Therapeutics, a review of this submission by the evidence review group (ERG) and evidence submitted by clinical experts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback